Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with reported cases having doubled since 1990. Today, CVDs account for 1 in 3 deaths worldwide, representing 32% of total global mortality, with heart attacks and ischemic strokes responsible for approximately 85% of these outcomes. The rising burden is strongly associated with population aging and an increasing prevalence of lifestyle-related risk factors, including hypertension, obesity, and diabetes. Economically, the impact is profound—annual CVD-related healthcare expenditures in the United States are projected to reach $1.49 trillion by 2050, while costs across the European Union have already exceeded $326.1 billion (2024).

Advancements in gene editing, biomarker discovery, digital biomarkers, and digital health platforms are accelerating the shift toward precision cardiology, enabling more personalized and predictive patient management. Biopharmaceutical innovators such as Avidity Biosciences and Verve Therapeutics are developing next-generation RNA-based and gene-targeted therapies, while consumer health technologies—including wearables from Apple, Fitbit, and Garmin—support continuous monitoring of physiological parameters. The integration of AI and advanced data analytics further enhances early detection, personalized monitoring, risk prediction, and disease management for cardiometabolic conditions. Digital technologies such as digital twins are transforming diagnostic accuracy and prognostic modeling, allowing clinicians to simulate treatment pathways and deliver tailored interventions. The increasing adoption of mechanistic modeling and multiscale simulations is helping define optimal therapeutic strategies, underscoring their role in propelling precision cardiology.

Within the clinical care continuum, solutions focused on dose optimization, reduced medication burden, and episodic risk management are gaining traction as healthcare providers seek to improve outcomes while minimizing treatment costs. Predictive analytics for treatment monitoring is gaining wider acceptance among clinicians, patients, and payers, supported by the gradual expansion of reimbursement frameworks for digital and precision-based interventions.

To strengthen evidence generation and promote equitable access, pharmaceutical companies are forming strategic partnerships with academic institutions, professional societies, government bodies, and payer organizations. These collaborations aim to integrate expert panels into industry decision-making processes and establish standardized, inclusive care pathways. Partnerships with agencies such as the American Heart Association (AHA) and the American College of Cardiology (ACC) have enabled companies, including Amgen and Novo Nordisk, to advance policy support, reimbursement alignment, and broader adoption of precision cardiology solutions.

Author: Aarti Siddhesh Chitale